150,000 Shares in Sanofi (NASDAQ:SNY) Acquired by Vestal Point Capital LP

Vestal Point Capital LP bought a new stake in Sanofi (NASDAQ:SNY) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 150,000 shares of the company’s stock, valued at approximately $8,644,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Barrow Hanley Mewhinney & Strauss LLC increased its stake in shares of Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after buying an additional 3,164,092 shares during the period. Magnetar Financial LLC increased its position in Sanofi by 1,153.1% in the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock valued at $121,605,000 after acquiring an additional 2,306,286 shares during the period. Jennison Associates LLC raised its stake in shares of Sanofi by 938.0% during the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after acquiring an additional 1,720,972 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in Sanofi by 28,890.2% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock worth $82,366,000 after buying an additional 1,424,289 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after acquiring an additional 1,370,232 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of Sanofi stock opened at $48.72 on Friday. The business has a 50-day simple moving average of $53.17 and a 200 day simple moving average of $52.15. Sanofi has a one year low of $45.22 and a one year high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market capitalization of $123.64 billion, a price-to-earnings ratio of 24.86, a PEG ratio of 1.23 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same period in the prior year, the firm earned $2.55 earnings per share. Sanofi’s revenue for the quarter was up 12.3% on a year-over-year basis. On average, research analysts anticipate that Sanofi will post 4.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of research analyst reports. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.